ConductScience.org, home

Paper40969260

Challenges and breakthroughs: current landscape and future prospects of CAR-T cell therapy clinical trials for solid tumors.

Guo J and 3 others. Front Oncol, 2025. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Challenges and breakthroughs: current landscape and future prospects of CAR-T cell therapy clinical trials for solid tumors. Papers, record 40969260. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40969260

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Challenges and breakthroughs: current landscape and future prospects of CAR-T cell therapy clinical trials for solid tumors.
PubMed
Journal
Front Oncol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
1.82, provisional
iCite
Revised in PubMed
2025-09-21
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Guo JJing
2Zhou CChunhe
3Zhao HHongmei
4Li HHuiyan

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References56

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134568831Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.Blood Cancer Discov2021https://conductscience.org/library/papers/34568831PubMed
239537919Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas.Nature2025https://conductscience.org/library/papers/39537919PubMed
31719465Expression of the Met/HGF receptor in normal and neoplastic human tissues.Oncogene1991https://conductscience.org/library/papers/1719465PubMed
435205742The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges.Cancers (Basel)2022https://conductscience.org/library/papers/35205742PubMed
539888581Obecabtagene Autoleucel: First Approval.Mol Diagn Ther2025https://conductscience.org/library/papers/39888581PubMed
632843493HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery.J Immunother Cancer2020https://conductscience.org/library/papers/32843493PubMed
727324746Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response.Prostate2016https://conductscience.org/library/papers/27324746PubMed
838822118The changing landscape of cancer cell therapies: clinical trials and real-world data.Nat Rev Drug Discov2024https://conductscience.org/library/papers/38822118PubMed
929385370Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med2018https://conductscience.org/library/papers/29385370PubMed
1038583184CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.Cancer Discov2024https://conductscience.org/library/papers/38583184PubMed
1134325726IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.J Hematol Oncol2021https://conductscience.org/library/papers/34325726PubMed
1239775044Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial.Nat Med2025https://conductscience.org/library/papers/39775044PubMed
1328366766Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers.Mol Ther2017https://conductscience.org/library/papers/28366766PubMed
1435738799PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages.J Immunother Cancer2022https://conductscience.org/library/papers/35738799PubMed
1533312759Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial.Oncoimmunology2020https://conductscience.org/library/papers/33312759PubMed
1635314843PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.Nat Med2022https://conductscience.org/library/papers/35314843PubMed
1738572751Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024https://conductscience.org/library/papers/38572751PubMed
1837377890Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma.Cancer Res Commun2023https://conductscience.org/library/papers/37377890PubMed
1933824268CAR-T cell therapy: current limitations and potential strategies.Blood Cancer J2021https://conductscience.org/library/papers/33824268PubMed
2038867077PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial.Nat Med2024https://conductscience.org/library/papers/38867077PubMed

See all 56 referencesDownload CSV of references

Cited by9

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
42827775In vivo CAR-T cell generation: a production-rate framework linking vector and cellular pharmacology.Front Immunol2026https://conductscience.org/library/papers/42827775PubMed
42814277Recent advancements and persisting challenges in the evolution of next generation car t cell therapy for solid malignancies: a comprehensive review.Immunol Res2026https://conductscience.org/library/papers/42814277PubMed
42811304Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma.BMC Cancer2026https://conductscience.org/library/papers/42811304PubMed
42741322Advances in CAR-T Cell Therapy: From Structural Design Innovations to Clinical Translation Challenges.J Cancer2026https://conductscience.org/library/papers/42741322PubMed
42517272The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions.Hum Vaccin Immunother2026https://conductscience.org/library/papers/42517272PubMed
42471452Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma.Cancer Immunol Immunother2026https://conductscience.org/library/papers/42471452PubMed
42363170Next-generation of mesothelin-targeted CAR-T cells secreting anti-PD-L1 scFv for potent immunotherapy against 3D patient-derived colorectal cancer organoids.BMC Med2026https://conductscience.org/library/papers/42363170PubMed
41802306Immunotherapy for microsatellite-stable colorectal cancer: overcoming resistance and exploring novel therapeutic strategies.Ann Coloproctol2026https://conductscience.org/library/papers/41802306PubMed
41335396Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations.Mol Biomed2025https://conductscience.org/library/papers/41335396PubMed

Download CSV of cited by

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40969260

GET https://conductscience.org/api/papers/v1/40969260/references?page=2